TY - JOUR T1 - Fatal Stimulation of Acute Myeloid Leukemia Blasts by Pegfilgrastim JF - Anticancer Research JO - Anticancer Res SP - 6747 LP - 6748 VL - 34 IS - 11 AU - CELINE DUVAL AU - STEPHANIE BOUCHER AU - JEAN-CHARLES MOULIN AU - BENEDICTE GOURIEUX AU - LAURENT MAUVIEUX AU - DOMINIQUE LEVEQUE AU - RAOUL HERBRECHT Y1 - 2014/11/01 UR - http://ar.iiarjournals.org/content/34/11/6747.abstract N2 - We herein report the case of a male patient with acute myeloid leukemia with fatal outcome attributable to pharmacokinetics of pegfilgrastim. Case Report: An unexplained blast proliferation in a patient with acute myeloid leukemia following cytotoxic induction chemotherapy was investigated in depth. Myeloblast hyperstimulation was likely related to pegfilgrastim, the long half-life of which extended the duration of side-effects, resulting in massive and rapidly fatal leukemia cell proliferation. Conclusion: Pegfilgrastim can cause unexpected deleterious effects in acute myeloid leukemia. We, thus, recommend administering drugs with a shorter half-life, such as filgrastim or lenograstim, to reduce infection incidence in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia. ER -